FR2856598A1 - Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale - Google Patents

Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale

Info

Publication number
FR2856598A1
FR2856598A1 FR0307659A FR0307659A FR2856598A1 FR 2856598 A1 FR2856598 A1 FR 2856598A1 FR 0307659 A FR0307659 A FR 0307659A FR 0307659 A FR0307659 A FR 0307659A FR 2856598 A1 FR2856598 A1 FR 2856598A1
Authority
FR
France
Prior art keywords
mmp
protein
tumor immunotherapy
peptides derived
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0307659A
Other languages
English (en)
Other versions
FR2856598B1 (fr
Inventor
Yannick Guilloux
Francine Jotereau
Emmanuelle Godefroy
Elisabeth Diez
Agnes Aubry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR0307659A priority Critical patent/FR2856598B1/fr
Priority to US10/561,951 priority patent/US7629439B2/en
Priority to EP04767441A priority patent/EP1635862A1/fr
Priority to JP2006516321A priority patent/JP2007520198A/ja
Priority to CA002529943A priority patent/CA2529943A1/fr
Priority to PCT/FR2004/001585 priority patent/WO2005000342A1/fr
Publication of FR2856598A1 publication Critical patent/FR2856598A1/fr
Application granted granted Critical
Publication of FR2856598B1 publication Critical patent/FR2856598B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Abstract

L'invention est relative à des peptides constituant des épitopes T de l'antigène MMP-2, présentés par le CMH I. Ces peptides sont utilisables notamment en immunothérapie anti-tumorale.
FR0307659A 2003-06-25 2003-06-25 Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale Expired - Fee Related FR2856598B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0307659A FR2856598B1 (fr) 2003-06-25 2003-06-25 Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
US10/561,951 US7629439B2 (en) 2003-06-25 2004-06-24 Peptides derived from the protein MMP-2, and the use thereof in antitumoral immunotherapy
EP04767441A EP1635862A1 (fr) 2003-06-25 2004-06-24 Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
JP2006516321A JP2007520198A (ja) 2003-06-25 2004-06-24 Ｍｍｐ−２タンパク質由来ペプチドおよび抗腫瘍免疫療法におけるその使用
CA002529943A CA2529943A1 (fr) 2003-06-25 2004-06-24 Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
PCT/FR2004/001585 WO2005000342A1 (fr) 2003-06-25 2004-06-24 Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0307659A FR2856598B1 (fr) 2003-06-25 2003-06-25 Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale

Publications (2)

Publication Number Publication Date
FR2856598A1 true FR2856598A1 (fr) 2004-12-31
FR2856598B1 FR2856598B1 (fr) 2005-10-28

Family

ID=33515388

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0307659A Expired - Fee Related FR2856598B1 (fr) 2003-06-25 2003-06-25 Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale

Country Status (6)

Country Link
US (1) US7629439B2 (fr)
EP (1) EP1635862A1 (fr)
JP (1) JP2007520198A (fr)
CA (1) CA2529943A1 (fr)
FR (1) FR2856598B1 (fr)
WO (1) WO2005000342A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481477B2 (en) 2010-01-12 2013-07-09 New York University Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors
CN103823068B (zh) * 2013-12-16 2016-05-25 周菊华 一种抗肿瘤淋巴细胞的鉴定方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045137A1 (fr) * 1996-05-31 1997-12-04 The Scripps Research Institute Procedes et compositions inhibant l'angiogenese
WO2001080811A2 (fr) * 2000-04-27 2001-11-01 The General Hospital Corporation Propeptide mmp-2 convenant comme antiangiogene ou antitumoral
WO2002098351A2 (fr) * 2001-06-01 2002-12-12 University Of Southern California Nouveau procede et nouvelle composition d'inhibition de l'angiogenese et de la croissance tumorale faisant intervenir des composes a base d'une sequence au sein de mmp-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2230795A1 (fr) * 1995-09-07 1997-03-13 Khandan Keyomarsi Variantes de la cycline e et leur utilisation
JP2000516201A (ja) * 1996-05-31 2000-12-05 ザ スクリップス リサーチ インスティテュート 血管形成阻害方法及び血管形成阻害に有用な組成物
RU2346043C2 (ru) * 2002-01-23 2009-02-10 Маттиас Рат Синтетические пептиды и способ профилактического и лечебного применения при инвазии и метастазировании рака

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045137A1 (fr) * 1996-05-31 1997-12-04 The Scripps Research Institute Procedes et compositions inhibant l'angiogenese
WO2001080811A2 (fr) * 2000-04-27 2001-11-01 The General Hospital Corporation Propeptide mmp-2 convenant comme antiangiogene ou antitumoral
WO2002098351A2 (fr) * 2001-06-01 2002-12-12 University Of Southern California Nouveau procede et nouvelle composition d'inhibition de l'angiogenese et de la croissance tumorale faisant intervenir des composes a base d'une sequence au sein de mmp-2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BROOKS P C ET AL: "Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 92, 6 February 1998 (1998-02-06), pages 391 - 400, XP002195424, ISSN: 0092-8674 *
EGEBLAD M. ET WERB Z.: "New functions for the matrix metalloproteinases in cancer progression.", NATURE REVIEWS CANCER, vol. 2, no. 3, March 2002 (2002-03-01), pages 161 - 174, XP009023724 *
MASSOVA I ET AL: "MATRIX METALLOPROTEINASES: STRUCTURES, EVOLUTION, AND DIVERSIFICATION", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 12, 1998, pages 1075 - 1095, XP002949725, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
FR2856598B1 (fr) 2005-10-28
WO2005000342A1 (fr) 2005-01-06
CA2529943A1 (fr) 2005-01-06
US20070264275A1 (en) 2007-11-15
EP1635862A1 (fr) 2006-03-22
JP2007520198A (ja) 2007-07-26
US7629439B2 (en) 2009-12-08

Similar Documents

Publication Publication Date Title
HUP0301789A2 (hu) Rekombináns anti CD40 ellenanyagok és használatuk
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
EA200401467A1 (ru) Пептиды, полученные из казеина, и их применение в терапии
FR20C1016I1 (fr)
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
GEP20053658B (en) Soluble CTLA4 Mutant Molecules and Uses Thereof
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
ATE209216T1 (de) Cyclosporin-derivate mit anti-hiv-wirkung
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
ATE484290T1 (de) Peptid mit antitumoraler wirkung
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
DE60332425D1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
FR2856598A1 (fr) Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
HUP0300997A2 (hu) A MIA-fehérje alkalmazása immunterápiában
WO2000052045A3 (fr) Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees
ATE442387T1 (de) Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
DK1301637T3 (da) DNA-vacciner, der koder for HIV accessoriske proteiner

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20120229